Stock Taper 
VCEL
$40.95
▼ DOWN 0.56% (-0.23)
KEY STATISTICS
Market Cap$2.10 B
52w High$49.32
52w Low$28.95
Dividend Yield—
Frequency—
P/E87.13
Volume491.25K
Shares Out.51.21M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Dominick C. Colangelo
COMPENSATION 2026
Salary$860,000
Stock Awards$3,964,630
Incentive Plan Pay$860,000
All Other Comp.$15,451
Total$11,156,368
ABOUT
SECTOR
Healthcare
WENT PUBLIC
February 4, 1997
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
398
PRICE TARGET
Target High$70.00
Target Low$46.00
Target Median$57.00
Target Consensus$57.50
UPCOMING EARNINGS
DateNov 5, 2026
DayThursday
Rev. Est.$77.98M
NOV
5
THU
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2013-10-16 | Reverse | 1:20 |
| 2010-02-18 | Reverse | 1:8 |
PRICE
$40.95 ▼ DOWN 0.56% (−$0.23)About Vericel Corporation
https://vcel.com ↗Vericel Corporation develops and markets cellular therapies like MACI and Epicel for sports medicine and burn care, with products including NexoBrid in preapproval stages.
INDUSTRY
Biotechnology
A PRODUCT VERICEL CORPORATION IS KNOWN FOR
MACI (autologous cultured chondrocytes on porcine collagen membrane)
MACI, Vericel’s flagship autologous cell therapy, uses a patient's own cells to repair knee cartilage defects, with recent FDA approval enabling less invasive arthroscopic delivery to potentially prevent osteoarthritis.
Revenue by Products
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
 | MACI Implants And Kits | $55.66M | $84.09M ▲ | $56.4M ▼ | $65.51M ▲ |
ETFS HOLDING THIS STOCK
ETFS HOLDING
181
LISTED HERE
26
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
81.90%
HOLDERS
423
TOP 12 OF 423 · RANKED BY POSITION SIZE
Blackrock, Inc.
Blackrock Inc.
Vanguard Group Inc
State Street Corp
Congress Asset Management Co /Ma
Waddell & Reed Financial Inc
Soleus Capital Management, L.P.
Conestoga Capital Advisors, LLC
William Blair Investment Management, LLC
Fmr LLC
Brown Capital Management LLC
Geneva Capital Management LLC
RATINGS SNAPSHOT
Overall rating: B-
Discounted Cash Flow3
Return On Equity3
Return On Assets4
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score2
INSIDER TRADES
★
DIRECTOR
MCLAUGHLIN KEVIN F
Purchase · 7.0K shares
2026-08-12
★
DIRECTOR
MCLAUGHLIN KEVIN F
Purchase · 7.0K shares
2026-08-12
★
OFFICER: CHIEF OPERATING OFFICER
Halpin Michael
Purchase · 10.0K shares
2026-08-03
★
OFFICER: CHIEF OPERATING OFFICER
Halpin Michael
Purchase · 10.0K shares
2026-08-03
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 3
NEUTRAL 1
4 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 EWTX | $42.76 | COMPARE |
 QURE | $48.72 | COMPARE |
 GPCR | $47.37 | COMPARE |
 VRDN | $23.08 | COMPARE |
 NUVB | $6.66 | COMPARE |
 HRMY | $39.21 | COMPARE |
 OCUL | $10.36 | COMPARE |
 MESO | $17.44 | COMPARE |